@inbook{43de705d7fc2486a91e5269c34089c5e,
title = "Multi-gene panel testing in breast cancer management",
abstract = "Hereditary predisposition accounts for approximately 10% of all breast cancers and is mostly associated with germline mutations in high-penetrance genes encoding for proteins participating in DNA repair through homologous recombination (BRCA1 and BRCA2). With the advent of massive parallel next-generation DNA sequencing, simultaneous analysis of multiple genes with a short turnaround time and at a low cost has become possible. The clinical validity and utility of multi-gene panel testing is getting better characterized as more data on the significance of moderate-penetrance genes are collected from large, cancer genetic testing studies. In this chapter, we attempt to provide a general guide for interpretation of panel gene testing in breast cancer and use of the information obtained for clinical decision-making.",
keywords = "BRCA1/2, Deleterious mutations, Gene panel testing, Hereditary breast cancer syndrome, Penetrance, Prevention",
author = "Christos Fountzilas and Kaklamani, {Virginia G.}",
note = "Publisher Copyright: {\textcopyright} 2018, Springer International Publishing AG.",
year = "2018",
doi = "10.1007/978-3-319-70197-4_8",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "121--140",
booktitle = "Cancer Treatment and Research",
}